Trinity Biotech Unveils CGM+: An AI-Native Platform Targeting the $260 Billion AI Wearable Market - Trinity Biotech (NASDAQ:TRIB)

Trinity Biotech Unveils CGM+: An AI-Native Platform Targeting the $260 Billion AI Wearable Market

WILSONVILLE, Ore. and DUBLIN, July 24, 2025 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on...

Trinity Biotech Unveils CGM+: An AI-Native Platform Targeting the $260 Billion AI Wearable Market - Trinity Biotech (NASDAQ:TRIB)

WILSONVILLE, Ore. and DUBLIN, July 24, 2025 (GLOBE NEWSWIRE) -- Trinity Biotech plc (NASDAQ:TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today unveiled its new flagship product, CGM+, a next-generation wearable biosensor platform designed for the $260 billion AI wearables market. Now in the later stages of device development, CGM+ is Trinity's new A…

BD announces wearable injector trial for subcutaneous delivery of biologics

Becton, Dickinson and Company (BD) has announced a trial utilising the BD Libertas Wearable Injector for subcutaneous delivery of biologics.The post BD announces wearable injector trial for subcutaneous delivery of biologics appeared first on Medical Device Network.

BD announces first pharma-sponsored clinical trial using BD Libertas wearable injector technology for biologic drugs - Express Pharma

BD (Becton, Dickinson and Company), a medical technology company, announces the first pharma-sponsored combination product clinical trial using the BD Libertas Wearable Injector for subcutaneous delivery of complex biologics.  The selection of BD Libertas Wearable Injector for this pharma-sponsored trial follows successful outcomes from more than 50 BD-conducted pre-clinical and clinical studies, including a device clinical study demonstrating e…

BD set for first pharma-sponsored clinical trial for wearable injector

The Libertas wearable injector. [Image courtesy of BD]BD (NYSE:BDX) today announced the first pharma-sponsored combination product clinical trial using its wearable injector technology. The study uses the BD Libertas wearable injector for the subcutaneous delivery of complex biologics. The company said it represents a significant advancement in accelerating innovation in drug-device combination products. It could provide greater flexibility for …

BD Announces First Pharma-Sponsored Clinical Trial Using BD Libertas™ Wearable Injector Technology for Biologic Drugs

FRANKLIN LAKES, N.J., July 23, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announces the first pharma-sponsored combination product clinical trial using the BD Libertas™ Wearable Injector for subcutaneous delivery of complex…